I also totally agree with DG's recent posts, especially the fact that the PH 4 trial is a marketing/commercialization tool geared toward promoting the product thru physicians.
As far as Abbie vs Abbott I do not agree, NexAct is designed first for generic drugs, delivering already approved drugs in a new way,
APRI can sell generic formulas just like anyone else, except make them there own with a new delivery system, also going to generics gets a drug to market faster than applying NexAct to a newly formulated drug. Abbott not Abvie retained all the generic drugs in the split. Alprostadil is a common generic drug.
As far as selling the co., no one will buy APRI until they have lots of proven revenue, IMO.
News 
Market Data 
Discover 
AI
